Table 1 MOG-IgG in patients with PPMS and SPMS as found in the present study and as reported in the literature
PPMS | SPMS | |
|---|---|---|
Jarius et al., present study | 139, none positive for MOG-IgG | 61, none positive for MOG-IgG |
Jarius et al., J Neuroinflammation 2016 [4] | 5, none positive for MOG-IgG | 11, none positive for MOG-IgG |
Martinez-Hernandez et al., JAMA Neurol 2015 [16] | 10, none positive for MOG-IgG | 9, none positive for MOG-IgG |
Höftberger et al., Mult Scler 2015 [17] | 10, none positive for MOG-IgG | 10, none positive for MOG-IgG |
Mader et al., J Neuroinflammation 2011 [11] | 8, none positive for MOG-IgG | 19, one borderline positive for MOG-IgG (1:160) |
Ramanathan et al., Neurol Neuroimmunol Neuroinflamm 2014 [18] | 2, none positive for MOG-IgG | 6, none positive for MOG-IgG |
Total | 0/174 | 1/116 (borderline result) |